NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
Clinical Trials
107 trialsNCT06110195 2026-03-31
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
Phase 1 Terminated
NCT03386357 2026-03-27
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT05316688 2026-02-25
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
University of Washington
Phase 1/2 Terminated
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04169074 2026-01-14
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
Phase 2 Terminated
NCT04801472 2026-01-05
OPPIDOM
Institut de cancérologie Strasbourg Europe
Phase NA Terminated
NCT04445064 2025-12-16
HN1901
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06338657 2025-09-16
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
University of Southern California
Phase 1 Terminated
NCT02892201 2025-07-29
Pembrolizumab in HNSCC With Residual Disease After Radiation
Yale University
Phase 2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05930938 2025-05-09
XXL_2022-01
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Terminated
NCT03053960 2025-04-30
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
Thomas Jefferson University
Terminated
NCT05322135 2025-04-09
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02827838 2025-03-17
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT04588038 2025-02-14
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
University of California, San Francisco
Phase 1 Terminated
NCT05457478 2025-01-24
The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy
OHSU Knight Cancer Institute
Phase NA Terminated
NCT04220775 2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03153982 2024-10-30
Ruxolitinib in Operable Head and Neck Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03601507 2024-04-17
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
University of Arizona
Phase 2 Terminated
NCT04624113 2024-02-21
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT03618134 2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02524275 2023-09-08
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Nebraska
Phase 2 Terminated
NCT03740100 2023-07-14
HNSCC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT03823131 2023-05-09
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
University of California, San Francisco
Phase 2 Terminated
NCT04110249 2023-04-10
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
Roswell Park Cancer Institute
Phase NA Terminated
NCT01827709 2023-04-03
Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma
Universitaire Ziekenhuizen KU Leuven
Phase NA Terminated
NCT02582008 2023-03-22
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT03258008 2022-12-16
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03513042 2022-12-06
ERM-PT-HNSCC
Leiden University Medical Center
Terminated
NCT01891695 2022-10-12
OPSCC N0 Nodal Control With Reduced IMRT
University of Virginia
Phase NA Terminated
NCT03862066 2022-08-11
Memory Phenotype and PD-1 Inhibition Response in Oral Cancer
Medical University of South Carolina
Terminated
NCT03090412 2022-06-02
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04428047 2022-04-06
ICING
UNICANCER
Phase 2 Terminated
NCT00566540 2021-11-26
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT02438995 2021-11-03
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Northwell Health
Phase 1 Terminated
NCT01895829 2021-09-21
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02177838 2021-04-21
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT02822482 2021-03-29
COPAN-ORL06
UNICANCER
Phase 1/2 Terminated
NCT03655444 2020-12-03
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Washington University School of Medicine
Phase 1/2 Terminated
NCT03276819 2020-10-08
UMBRELLA
Centre Leon Berard
Phase NA Terminated
NCT02464137 2020-08-20
HYDRA
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02236936 2020-05-01
AGMT_HNO_PN
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 3 Terminated
NCT03463161 2020-01-27
ORKA
University of Chicago
Phase 2 Terminated
NCT02429089 2020-01-09
CETLEE011
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1 Terminated
NCT00408252 2019-09-19
Efficacy of SU 011248 in Head And Neck Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT01987375 2019-06-24
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Stanford University
Phase 1 Terminated